Evidence map›Paper›PMID 24080872›Full record

ArticleKidney international2013

Dietary phosphate: the challenges of exploring its role in FGF23 regulation.

Marta Christov, Harald Jüppner

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Kidney international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. FGF-based drug discovery: advances and challenges.Nature reviews. Drug discovery · 2025
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Marta Christov1] Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA [2] Division of Nephrology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Harald Jüppner
Beth Israel Deaconess Medical Center · USHarvard University · US

Funding

Dissecting the Mechanisms that control FGF23K08DK093608 · NIDDK · NEW YORK MEDICAL COLLEGE · PI CHRISTOV, MARTA · 2012 to 2016
$752k
NIDDK NIH HHS K08 DK093608
6 · The paper itself

Abstract

Fibroblast growth factor 23 (FGF23) is an important regulator of phosphate homeostasis, yet efforts to control its circulating levels by manipulating dietary phosphate intake in humans and animals with normal or impaired kidney function have yielded conflicting results. In the study by Zhang et al., severe phosphate restriction in a genetic mouse model of progressive kidney dysfunction failed to cause a uniform FGF23 reduction, again highlighting the complexity of FGF23 regulation.

Indexed as

Acute Kidney InjuryAnimalsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsHumansHypophosphatemia, FamilialMaleNephritis, HereditaryPhosphatesRenal Insufficiency, ChronicSignal TransductionFGF23 protein, humanFgf23 protein, mouseFibroblast Growth Factor-23Fibroblast Growth FactorsPhosphates

Identifiers

PMID24080872
OpenAlexW2022454899

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.